NCT05481359Completed
AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation
A Post Market, Global Registry to Evaluate the Identification of Atrial Fibrillation Sources Using Electrographic Flow (EGF™) Mapping System to Guide Ablation Therapy in Patients With Atrial Fibrillation in Real-world Setting.
Source: ClinicalTrials.gov · Last updated 10 Apr 2025
Brief summary (registry, in English)
This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 25 (actual)
- First submitted
- 28 Jul 2022
- Start date
- 12 Sept 2022
- Primary completion date
- 27 Oct 2022
- Lead sponsor
- Ablacon, Inc.
- Diseases
- Atrial fibrillation
- NCT number
- NCT05481359
What you commit to
- Study type: Observational
- Participants enrolled: 25
- From 12 Sept 2022 to the primary completion date, 27 Oct 2022
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects who are not candidates for cardiac ablation procedures.
- Presence of anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or comply with follow-up requirements.
Other
- Pregnant or nursing.
Who the study is looking for
- Suitable candidate for intra-cardiac mapping and ablation of arrhythmias.
- Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law.
- Subjects with a history of documented symptomatic atrial fibrillation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
| Medicover Hospital Coordinator of this site? Confirm its status | Warsaw | Poland | Unknown status |
| Piedmont Healthcare Coordinator of this site? Confirm its status | Athens | United States | Unknown status |
| Piedmont Atlanta Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Mount Sinai Hospital Coordinator of this site? Confirm its status | New York | United States | Unknown status |
Related publications
- Characterization of AF Recurrence and Substrate Health by Electrographic Flow (EGF) Consistency in EGF Mapping.J Cardiovasc Electrophysiol · 2026 · PMID 42623431
- Electrographic flow (EGF) mapping reveals sex-based differences in EGF patterns with women concentrated in phenotypes that benefit from EGF-guided ablation.J Interv Card Electrophysiol · 2026 · PMID 41498861
This page is information, not medical advice. Discuss any trial with your doctor.